Published in Healthcare Finance, Tax and Law Weekly, July 11th, 2007
The combined entity has simultaneously closed a Series A financing round of Euro 20.6 million (US$ 27.6 million) to ensure the rapid development of the company's pipeline of compounds targeted to treat Alzheimer's disease and chronic inflammatory diseases. TVM Capital and HBM BioVentures (Cayman) Ltd. financed together with IBG Beteiligungsgesellschaft Sachsen-Anhalt mbH (IBG), Sachsen LB Corporate Finance...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Finance, Tax and Law Weekly